当前位置: 首页 >> 检索结果
401. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.
作者: Sripal Bangalore.;Sunil Kumar.;Iryna Lobach.;Franz H Messerli.
来源: Circulation. 2011年123卷24期2799-810, 9 p following 810页
Most guidelines for treatment of hypertension recommend a blood pressure (BP) goal of <140/90 mm Hg, and a more aggressive goal of <130/80 mm Hg for patients with diabetes mellitus. However, in the recent Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, a lower BP was not beneficial. The optimal BP target in subjects with diabetes mellitus or those with impaired fasting glucose/glucose tolerance is therefore not well defined.
402. A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease.
作者: Philipp S Wild.;Tanja Zeller.;Arne Schillert.;Silke Szymczak.;Christoph R Sinning.;Arne Deiseroth.;Renate B Schnabel.;Edith Lubos.;Till Keller.;Medea S Eleftheriadis.;Christoph Bickel.;Hans J Rupprecht.;Sandra Wilde.;Heidi Rossmann.;Patrick Diemert.;L Adrienne Cupples.;Claire Perret.;Jeanette Erdmann.;Klaus Stark.;Marcus E Kleber.;Stephen E Epstein.;Benjamin F Voight.;Kari Kuulasmaa.;Mingyao Li.;Arne S Schäfer.;Norman Klopp.;Peter S Braund.;Hendrik B Sager.;Serkalem Demissie.;Carole Proust.;Inke R König.;Heinz-Erich Wichmann.;Wibke Reinhard.;Michael M Hoffmann.;Jarmo Virtamo.;Mary Susan Burnett.;David Siscovick.;Per Gunnar Wiklund.;Liming Qu.;Nour Eddine El Mokthari.;John R Thompson.;Annette Peters.;Albert V Smith.;Emmanuelle Yon.;Jens Baumert.;Christian Hengstenberg.;Winfried März.;Philippe Amouyel.;Joseph Devaney.;Stephen M Schwartz.;Olli Saarela.;Nehal N Mehta.;Diana Rubin.;Kaisa Silander.;Alistair S Hall.;Jean Ferrieres.;Tamara B Harris.;Olle Melander.;Frank Kee.;Hakon Hakonarson.;Juergen Schrezenmeir.;Vilmundur Gudnason.;Roberto Elosua.;Dominique Arveiler.;Alun Evans.;Daniel J Rader.;Thomas Illig.;Stefan Schreiber.;Joshua C Bis.;David Altshuler.;Maryam Kavousi.;Jaqueline C M Witteman.;Andre G Uitterlinden.;Albert Hofman.;Aaron R Folsom.;Maja Barbalic.;Eric Boerwinkle.;Sekar Kathiresan.;Muredach P Reilly.;Christopher J O'Donnell.;Nilesh J Samani.;Heribert Schunkert.;Francois Cambien.;Karl J Lackner.;Laurence Tiret.;Veikko Salomaa.;Thomas Munzel.;Andreas Ziegler.;Stefan Blankenberg.
来源: Circ Cardiovasc Genet. 2011年4卷4期403-12页
eQTL analyses are important to improve the understanding of genetic association results. We performed a genome-wide association and global gene expression study to identify functionally relevant variants affecting the risk of coronary artery disease (CAD).
403. Copy number variation in glutathione S-transferases M1 and T1 and ischemic vascular disease: four studies and meta-analyses.
作者: Marianne S Nørskov.;Ruth Frikke-Schmidt.;Steffen Loft.;Henrik Sillesen.;Peer Grande.;Børge G Nordestgaard.;Anne Tybjaerg-Hansen.
来源: Circ Cardiovasc Genet. 2011年4卷4期418-28页
Glutathione S-transferases (GSTs) M1 and T1 detoxify products of oxidative stress and may protect against atherosclerosis and ischemic vascular disease (IVD). We tested the hypothesis that copy number variation (CNV) in GSTM1 and GSTT1 genes, known to be associated with stepwise decreases in catalytic activity, predict risk of IVD.
404. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia.
作者: Evan A Stein.;Harold Bays.;Dennis O'Brien.;Jim Pedicano.;Edward Piper.;Andrea Spezzi.
来源: Circulation. 2011年123卷18期1974-85页
Lapaquistat acetate is a squalene synthase inhibitor investigated for the treatment of hypercholesterolemia.
405. Genetic predictors of fibrin D-dimer levels in healthy adults.
作者: Nicholas L Smith.;Jennifer E Huffman.;David P Strachan.;Jie Huang.;Abbas Dehghan.;Stella Trompet.;Lorna M Lopez.;So-Youn Shin.;Jens Baumert.;Veronique Vitart.;Joshua C Bis.;Sarah H Wild.;Ann Rumley.;Qiong Yang.;Andre G Uitterlinden.;David J Stott.;Gail Davies.;Angela M Carter.;Barbara Thorand.;Ozren Polašek.;Barbara McKnight.;Harry Campbell.;Alicja R Rudnicka.;Ming-Huei Chen.;Brendan M Buckley.;Sarah E Harris.;Annette Peters.;Drazen Pulanic.;Thomas Lumley.;Anton J M de Craen.;David C Liewald.;Christian Gieger.;Susan Campbell.;Ian Ford.;Alan J Gow.;Michelle Luciano.;David J Porteous.;Xiuqing Guo.;Naveed Sattar.;Albert Tenesa.;Mary Cushman.;P Eline Slagboom.;Peter M Visscher.;Tim D Spector.;Thomas Illig.;Igor Rudan.;Edwin G Bovill.;Alan F Wright.;Wendy L McArdle.;Geoffrey Tofler.;Albert Hofman.;Rudi G J Westendorp.;John M Starr.;Peter J Grant.;Mahir Karakas.;Nicholas D Hastie.;Bruce M Psaty.;James F Wilson.;Gordon D O Lowe.;Christopher J O'Donnell.;Jacqueline C M Witteman.;J Wouter Jukema.;Ian J Deary.;Nicole Soranzo.;Wolfgang Koenig.;Caroline Hayward.
来源: Circulation. 2011年123卷17期1864-72页
Fibrin fragment D-dimer, one of several peptides produced when crosslinked fibrin is degraded by plasmin, is the most widely used clinical marker of activated blood coagulation. To identity genetic loci influencing D-dimer levels, we performed the first large-scale, genome-wide association search.
406. Safety of pacemaker reuse: a meta-analysis with implications for underserved nations.
作者: Timir S Baman.;Pascal Meier.;Joshua Romero.;Lindsey Gakenheimer.;James N Kirkpatrick.;Patricia Sovitch.;Hakan Oral.;Kim A Eagle.
来源: Circ Arrhythm Electrophysiol. 2011年4卷3期318-23页
A large disparity in medical health care is clearly evident between developed and underserved nations in the field of cardiac electrophysiology, specifically pacemaker implantation. This study aimed to assess the safety of pacemaker reuse.
407. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.
作者: Allan D Sniderman.;Ken Williams.;John H Contois.;Howard M Monroe.;Matthew J McQueen.;Jacqueline de Graaf.;Curt D Furberg.
来源: Circ Cardiovasc Qual Outcomes. 2011年4卷3期337-45页
Whether apolipoprotein B (apoB) or non-high-density lipoprotein cholesterol (HDL-C) adds to the predictive power of low-density lipoprotein cholesterol (LDL-C) for cardiovascular risk remains controversial.
408. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis.
作者: Patricia Jabre.;Véronique L Roger.;Mohammad H Murad.;Alanna M Chamberlain.;Larry Prokop.;Frédéric Adnet.;Xavier Jouven.
来源: Circulation. 2011年123卷15期1587-93页
Atrial fibrillation (AF) is a common finding in patients with myocardial infarction (MI). Atrial fibrillation is not generally perceived by clinicians as a critical event during the acute phase of MI; however, its prognostic influence in MI remains controversial. Furthermore, contradictory data exist concerning the risk of death according to AF timing. This article, a systematic review and first meta-analysis, aims to quantify the mortality risk associated with AF in MI patients and its timing.
409. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies.
作者: Giuseppe Patti.;Christopher P Cannon.;Sabina A Murphy.;Simona Mega.;Vincenzo Pasceri.;Carlo Briguori.;Antonio Colombo.;Kyeong Ho Yun.;Myung Ho Jeong.;Jung-Sun Kim.;Donghoon Choi.;Huseyin Bozbas.;Masayoshi Kinoshita.;Keiichi Fukuda.;Xin-Wei Jia.;Hidehiko Hara.;Serkan Cay.;Germano Di Sciascio.
来源: Circulation. 2011年123卷15期1622-32页
Previous studies suggested that statin pretreatment reduces cardiac events in patients undergoing percutaneous coronary intervention. However, most data were observational, and single randomized trials included limited numbers of patients.
410. Meta-analysis: impact of drug class on adherence to antihypertensives.
作者: Ian M Kronish.;Mark Woodward.;Ziad Sergie.;Gbenga Ogedegbe.;Louise Falzon.;Devin M Mann.
来源: Circulation. 2011年123卷15期1611-21页
Observational studies suggest that there are differences in adherence to antihypertensive medications in different classes. Our objective was to quantify the association between antihypertensive drug class and adherence in clinical settings.
411. Dense genotyping of candidate gene loci identifies variants associated with high-density lipoprotein cholesterol.
作者: Andrew C Edmondson.;Peter S Braund.;Ioannis M Stylianou.;Amit V Khera.;Christopher P Nelson.;Megan L Wolfe.;Stephanie L Derohannessian.;Brendan J Keating.;Liming Qu.;Jing He.;Martin D Tobin.;Maciej Tomaszewski.;Jens Baumert.;Norman Klopp.;Angela Döring.;Barbara Thorand.;Mingyao Li.;Muredach P Reilly.;Wolfgang Koenig.;Nilesh J Samani.;Daniel J Rader.
来源: Circ Cardiovasc Genet. 2011年4卷2期145-55页
Plasma levels of high-density lipoprotein cholesterol (HDL-C) are known to be heritable, but only a fraction of the heritability is explained. We used a high-density genotyping array containing single-nucleotide polymorphisms (SNPs) from HDL-C candidate genes selected on known biology of HDL-C metabolism, mouse genetic studies, and human genetic association studies. SNP selection was based on tagging SNPs and included low-frequency nonsynonymous SNPs.
412. Additional ablation of complex fractionated atrial electrograms after pulmonary vein isolation in patients with atrial fibrillation: a meta-analysis.
作者: Wei-ju Li.;Yong-yi Bai.;Hong-yin Zhang.;Ri-bo Tang.;Cheng-long Miao.;Cai-hua Sang.;Xian-dong Yin.;Jian-zeng Dong.;Chang-sheng Ma.
来源: Circ Arrhythm Electrophysiol. 2011年4卷2期143-8页
The efficacy of additional complex fractionated atrial electrogram (CFAE) ablation after pulmonary vein antrum isolation (PVAI) in patients with atrial fibrillation (AF) remains controversial. This meta-analysis was performed to assess the additional efficacy of CFAEs ablation after a single procedure without antiarrhythmic drugs.
413. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels.
作者: Abbas Dehghan.;Josée Dupuis.;Maja Barbalic.;Joshua C Bis.;Gudny Eiriksdottir.;Chen Lu.;Niina Pellikka.;Henri Wallaschofski.;Johannes Kettunen.;Peter Henneman.;Jens Baumert.;David P Strachan.;Christian Fuchsberger.;Veronique Vitart.;James F Wilson.;Guillaume Paré.;Silvia Naitza.;Megan E Rudock.;Ida Surakka.;Eco J C de Geus.;Behrooz Z Alizadeh.;Jack Guralnik.;Alan Shuldiner.;Toshiko Tanaka.;Robert Y L Zee.;Renate B Schnabel.;Vijay Nambi.;Maryam Kavousi.;Samuli Ripatti.;Matthias Nauck.;Nicholas L Smith.;Albert V Smith.;Jouko Sundvall.;Paul Scheet.;Yongmei Liu.;Aimo Ruokonen.;Lynda M Rose.;Martin G Larson.;Ron C Hoogeveen.;Nelson B Freimer.;Alexander Teumer.;Russell P Tracy.;Lenore J Launer.;Julie E Buring.;Jennifer F Yamamoto.;Aaron R Folsom.;Eric J G Sijbrands.;James Pankow.;Paul Elliott.;John F Keaney.;Wei Sun.;Antti-Pekka Sarin.;João D Fontes.;Sunita Badola.;Brad C Astor.;Albert Hofman.;Anneli Pouta.;Karl Werdan.;Karin H Greiser.;Oliver Kuss.;Henriette E Meyer zu Schwabedissen.;Joachim Thiery.;Yalda Jamshidi.;Ilja M Nolte.;Nicole Soranzo.;Timothy D Spector.;Henry Völzke.;Alexander N Parker.;Thor Aspelund.;David Bates.;Lauren Young.;Kim Tsui.;David S Siscovick.;Xiuqing Guo.;Jerome I Rotter.;Manuela Uda.;David Schlessinger.;Igor Rudan.;Andrew A Hicks.;Brenda W Penninx.;Barbara Thorand.;Christian Gieger.;Joe Coresh.;Gonneke Willemsen.;Tamara B Harris.;Andre G Uitterlinden.;Marjo-Riitta Järvelin.;Kenneth Rice.;Dörte Radke.;Veikko Salomaa.;Ko Willems van Dijk.;Eric Boerwinkle.;Ramachandran S Vasan.;Luigi Ferrucci.;Quince D Gibson.;Stefania Bandinelli.;Harold Snieder.;Dorret I Boomsma.;Xiangjun Xiao.;Harry Campbell.;Caroline Hayward.;Peter P Pramstaller.;Cornelia M van Duijn.;Leena Peltonen.;Bruce M Psaty.;Vilmundur Gudnason.;Paul M Ridker.;Georg Homuth.;Wolfgang Koenig.;Christie M Ballantyne.;Jacqueline C M Witteman.;Emelia J Benjamin.;Markus Perola.;Daniel I Chasman.
来源: Circulation. 2011年123卷7期731-8页
C-reactive protein (CRP) is a heritable marker of chronic inflammation that is strongly associated with cardiovascular disease. We sought to identify genetic variants that are associated with CRP levels.
414. The effect of survival bias on case-control genetic association studies of highly lethal diseases.
作者: Christopher D Anderson.;Michael A Nalls.;Alessandro Biffi.;Natalia S Rost.;Steven M Greenberg.;Andrew B Singleton.;James F Meschia.;Jonathan Rosand.
来源: Circ Cardiovasc Genet. 2011年4卷2期188-96页
Survival bias is the phenomenon by which individuals are excluded from analysis of a trait because of mortality related to the expression of that trait. In genetic association studies, variants increasing risk for disease onset as well as risk of disease-related mortality (lethality) could be difficult to detect in genetic association case-control designs, possibly leading to underestimation of a variant's effect on disease risk.
415. Heterogeneity of the phenotypic definition of coronary artery disease and its impact on genetic association studies.
作者: Georgios D Kitsios.;Issa J Dahabreh.;Thomas A Trikalinos.;Christopher H Schmid.;Gordon S Huggins.;David M Kent.
来源: Circ Cardiovasc Genet. 2011年4卷1期58-67页
Variability in phenotypic characterization of coronary artery disease (CAD) may contribute to the heterogeneity of genetic association studies, and more consistency in phenotype definitions might improve replication of genetic associations. We assessed the extent of phenotypic heterogeneity and quantified its impact in a large literature sample of association studies.
416. Drug-eluting or bare metal stents for the treatment of saphenous vein graft disease: a Bayesian meta-analysis.
作者: Jean-Michel Paradis.;Patrick Bélisle.;Lawrence Joseph.;Olivier F Bertrand.;Robert DeLarochellière.;Jean-Pierre Déry.;Eric Larose.;Josep Rodés-Cabau.;Stéphane Rinfret.
来源: Circ Cardiovasc Interv. 2010年3卷6期565-76页
Observational studies and randomized, controlled trials have yielded uncertain results regarding the benefits of drug-eluting stents (DES) for the treatment of saphenous vein graft (SVG) disease. The objective of this meta-analysis was to assess the cumulative evidence regarding the efficacy and effectiveness of DES to treat SVG compared with bare metal stent (BMS).
418. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
作者: Ravinder K Wali.;Malini Iyengar.;Gerald J Beck.;David M Chartyan.;Michel Chonchol.;Mary Ann Lukas.;Christopher Cooper.;Jonathan Himmelfarb.;Matthew R Weir.;Tomas Berl.;William L Henrich.;Alfred K Cheung.
来源: Circ Heart Fail. 2011年4卷1期18-26页
The safety and efficacy of different types of β-blocker therapy in patients with non-dialysis-dependent chronic kidney disease (CKD) and systolic heart failure (HF) are not well described. We assessed whether treatment of systolic HF with carvedilol is efficacious and safe in adults with CKD.
419. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis.
作者: Meng Lee.;Jeffrey L Saver.;Wen-Hung Huang.;Jessica Chow.;Kuo-Hsuan Chang.;Bruce Ovbiagele.
来源: Circ Cardiovasc Qual Outcomes. 2010年3卷6期675-83页
Chronic kidney disease is a growing public health problem that carries substantial risk for cardiovascular disease (CVD). Single studies have differentially examined the role of cystatin C, a novel renal index, with varying cut-point use. We undertook a meta-analysis of prospective studies to properly assess the link between cystatin C (dichotomized and continuous) versus CVD.
420. Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls.
作者: Michael Preuss.;Inke R König.;John R Thompson.;Jeanette Erdmann.;Devin Absher.;Themistocles L Assimes.;Stefan Blankenberg.;Eric Boerwinkle.;Li Chen.;L Adrienne Cupples.;Alistair S Hall.;Eran Halperin.;Christian Hengstenberg.;Hilma Holm.;Reijo Laaksonen.;Mingyao Li.;Winfried März.;Ruth McPherson.;Kiran Musunuru.;Christopher P Nelson.;Mary Susan Burnett.;Stephen E Epstein.;Christopher J O'Donnell.;Thomas Quertermous.;Daniel J Rader.;Robert Roberts.;Arne Schillert.;Kari Stefansson.;Alexandre F R Stewart.;Gudmar Thorleifsson.;Benjamin F Voight.;George A Wells.;Andreas Ziegler.;Sekar Kathiresan.;Muredach P Reilly.;Nilesh J Samani.;Heribert Schunkert.; .
来源: Circ Cardiovasc Genet. 2010年3卷5期475-83页
Recent genome-wide association studies (GWAS) of myocardial infarction (MI) and other forms of coronary artery disease (CAD) have led to the discovery of at least 13 genetic loci. In addition to the effect size, power to detect associations is largely driven by sample size. Therefore, to maximize the chance of finding novel susceptibility loci for CAD and MI, the Coronary ARtery DIsease Genome-wide Replication And Meta-analysis (CARDIoGRAM) consortium was formed.
|